Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 13/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.70 |
| ▸ | TSHR | P16473 | 11/20 | 0.70 |
| ▸ | LMNA | P02545 | 11/20 | 0.70 |
| ▸ | USP2 | O75604 | 9/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.70 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 3/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117297 | 0.90 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL3110729 | 0.87 | APP (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL3110831 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL4859994 | 0.83 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL9776789 | 0.82 | APP (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL12170163 | 0.82 | KCNA5 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL12175940 | 0.82 | SLC2A1 (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL4864864 | 0.82 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL3121034 | 0.81 | APP (0.79) | APPPDE5AMEN1KMT2A | |
| SCHEMBL20119650 | 0.81 | SMN1; SMN2 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2006074187-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | CYP1A2 2066/4885CYP3A4 1067/4885CYP2D6 1533/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 1881/4885CYP3A4 961/4885CYP2D6 1204/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP1A2 2087/4885CYP3A4 975/4885CYP2D6 1343/4885 |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | CASP3, CASP7, BAD | CYP1A2 2065/4885CYP3A4 1789/4885CYP2D6 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.